Innoviva (INVA) Dividends Paid - Common Growth (3y) (2017 - 2022)
Analysis
Innoviva (INVA) Dividends Paid - Common Growth (3y) (2017 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Paid (Common) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.26% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 87.79% |
| Jun 30, 2022 | 1,370.90% |
| Mar 31, 2022 | 833.46% |
| Sep 30, 2021 | 185.65% |
| Jun 30, 2021 | 192.09% |
| Mar 31, 2021 | 518.41% |
| Dec 31, 2020 | 164.99% |
| Jun 30, 2020 | 572.25% |
| Mar 31, 2020 | 517.95% |
| Sep 30, 2019 | 487.45% |
| Jun 30, 2019 | -71.08% |
| Mar 31, 2019 | -77.68% |
| Dec 31, 2018 | 154.07% |
| Sep 30, 2018 | -59.11% |
| Jun 30, 2018 | -69.76% |
| Mar 31, 2018 | -85.38% |
| Jun 30, 2017 | -94.76% |